GIVINOSTAT Emerging Drug Insight and Market Forecast - 2032

“GIVINOSTAT Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about GIVINOSTAT for Polycythemia Vera in the 7MM. A detailed picture of the GIVINOSTAT for Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the GIVINOSTAT for Polycythemia Vera. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the GIVINOSTAT market forecast, analysis for Polycythemia Vera in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Polycythemia Vera.

Drug Summary

GIVINOSTAT (ITF2357) is an orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. GIVINOSTAT inhibits class I and class II HDACs, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. At low nonapoptotic concentrations, this agent inhibits the production of pro-inflammatory cytokines such as tumor necrosis factor- (TNF-), interleukin-1 (IL-1), IL-6, and interferon-gamma. This reduces the expression of tumor necrosis factor (TNF), interleukin 1α and β, and interleukin. It has also been shown to activate the intrinsic apoptotic pathway, inducing apoptosis in hepatoma cells and leukemic cells. This agent may also exhibit anti-angiogenic activity, inhibiting the production of angiogenic factors such as IL-6 and vascular endothelial cell growth factor (VEGF) by bone marrow stromal cells.

Patients with PV have abnormalities in a gene responsible for producing an enzyme known as Janus kinase 2 (JAK2). JAK2 is involved in the reproduction and growth of red blood cells. In PV, JAK2 is over-activated. GIVINOSTAT is thought to work by reducing the levels of JAK2. In patients with polycythemia, the reduction of mutant JAK2 concentrations by GIVINOSTAT is believed to slow down the abnormal growth of erythrocytes and ameliorate the symptoms of the disease.  

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the GIVINOSTAT description, mechanism of action, dosage and administration, research and development activities in Polycythemia Vera.
• Elaborated details on GIVINOSTAT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the GIVINOSTAT research and development activity in Polycythemia Vera details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around GIVINOSTAT.
• The report contains forecasted sales of GIVINOSTAT for Polycythemia Vera till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Polycythemia Vera.
• The report also features the SWOT analysis with analyst views for GIVINOSTAT in Polycythemia Vera.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

GIVINOSTAT Analytical Perspective

In-depth GIVINOSTAT Market Assessment

This report provides a detailed market assessment of GIVINOSTAT in Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

GIVINOSTAT Clinical Assessment

The report provides the clinical trials information of GIVINOSTAT for Polycythemia Vera covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Polycythemia Vera is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence GIVINOSTAT dominance.
• Other emerging products for Polycythemia Vera are expected to give tough market competition to GIVINOSTAT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of GIVINOSTAT in Polycythemia Vera.
• The in-depth analysis of the forecasted sales data of GIVINOSTAT from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GIVINOSTAT in Polycythemia Vera.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of GIVINOSTAT?
• What is the clinical trial status of the study related to GIVINOSTAT in Polycythemia Vera and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the GIVINOSTAT development?
• What are the key designations that have been granted to GIVINOSTAT for Polycythemia Vera?
• What is the forecasted market scenario of GIVINOSTAT for Polycythemia Vera?
• What are the forecasted sales of GIVINOSTAT in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Polycythemia Vera and how are they giving competition to GIVINOSTAT for Polycythemia Vera?
• Which are the late-stage emerging therapies under development for the treatment of Polycythemia Vera?

This product will be delivered within 2 business days.